Advyzon Investment Management LLC Makes New $715,000 Investment in AbbVie Inc. (NYSE:ABBV)

Advyzon Investment Management LLC bought a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,023 shares of the company's stock, valued at approximately $715,000.

Several other hedge funds and other institutional investors have also made changes to their positions in ABBV. GGM Financials LLC raised its stake in AbbVie by 0.7% during the third quarter. GGM Financials LLC now owns 6,895 shares of the company's stock valued at $1,362,000 after buying an additional 50 shares during the last quarter. Dillon & Associates Inc. grew its holdings in AbbVie by 0.8% during the third quarter. Dillon & Associates Inc. now owns 6,914 shares of the company's stock valued at $1,362,000 after purchasing an additional 52 shares during the period. WFA Asset Management Corp grew its holdings in AbbVie by 0.8% during the third quarter. WFA Asset Management Corp now owns 7,003 shares of the company's stock valued at $1,383,000 after purchasing an additional 55 shares during the period. Carr Financial Group Corp grew its holdings in AbbVie by 1.1% during the third quarter. Carr Financial Group Corp now owns 5,274 shares of the company's stock valued at $1,041,000 after purchasing an additional 56 shares during the period. Finally, Wealthstream Advisors Inc. grew its holdings in AbbVie by 3.0% during the third quarter. Wealthstream Advisors Inc. now owns 1,954 shares of the company's stock valued at $386,000 after purchasing an additional 56 shares during the period. 70.23% of the stock is owned by institutional investors.

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm's stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the sale, the senior vice president now owns 6,983 shares of the company's stock, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.25% of the company's stock.

AbbVie Trading Up 0.6 %

Shares of NYSE:ABBV traded up $1.15 during trading on Friday, hitting $202.03. The company had a trading volume of 5,879,957 shares, compared to its average volume of 5,370,269. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.54. The company has a fifty day simple moving average of $181.25 and a two-hundred day simple moving average of $186.41. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The stock has a market cap of $356.64 billion, a price-to-earnings ratio of 84.18, a price-to-earnings-growth ratio of 1.61 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same period in the previous year, the company earned $2.79 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be given a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.25%. AbbVie's payout ratio is 273.33%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Guggenheim boosted their price objective on AbbVie from $212.00 to $214.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Morgan Stanley boosted their price objective on AbbVie from $224.00 to $239.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Citigroup boosted their price objective on AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Wolfe Research assumed coverage on AbbVie in a research report on Friday, November 15th. They issued an "outperform" rating and a $205.00 price objective on the stock. Finally, BMO Capital Markets boosted their price objective on AbbVie from $208.00 to $215.00 and gave the company an "outperform" rating in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.